Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery

被引:26
|
作者
Respicio, Laurel [2 ]
Nair, Pravin A. [1 ]
Huang, Qing [1 ]
Anil, Burcu [1 ]
Tracz, Sylvia [1 ]
Truglio, James J. [3 ]
Kisker, Caroline [4 ]
Raleigh, Daniel P. [1 ]
Ojima, Iwao [1 ]
Knudson, Dennis L. [5 ]
Tonge, Peter J. [1 ]
Slayden, Richard A. [2 ]
机构
[1] SUNY Stony Brook, Dept Chem, Inst Chem Biol & Drug Discovery, Stony Brook, NY 11794 USA
[2] Colorado State Univ, Dept Microbiol & Immunol Pathol, Mycobacteria Res Labs, Rocky Mt Reg Ctr Excellence, Ft Collins, CO 80523 USA
[3] SUNY Stony Brook, Struct Biol Ctr, Stony Brook, NY 11794 USA
[4] Univ Wurzburg, Inst Biol Struct, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany
[5] Colorado State Univ, Dept Bioagr Sci & Pest Management, Ft Collins, CO 80523 USA
关键词
Mycobacterium tuberculosis; cell division; FtsZ; septum inhibition; drug discovery;
D O I
10.1016/j.tube.2008.03.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A temperature sensitive mutation in the cell, division protein FtsZ was used in combination with transcriptional analysis to identify biomarkers for inhibition of septum formation. Crystallography and modeling revealed that the glycine for aspartate substitution at amino acid 210 was located in helix 8 of the protein, adjacent to the T7 synergy loop. To verify the molecular behavior of FtSZ(D210G), the in vitro activity and structural stability were evaluated as a function of temperature. These analyses confirmed that the FtsZ(D21OG) mutant had reduced GTPase and polymerization activity compared to wild-type FtsZ, and CD spectroscopy demonstrated that both FtsZD21OG and wild-type FtsZ had similar structure and stability. Significantly, the FtsZD21OG merodiploid strain of A tuberculosis had compromised growth at 37 degrees C, substantiating the suitability of FtSZ(D21OG) as a molecular toot for global analysis in response to improper FtsZ polymerization and septum inhibition. Advanced model-based bioinformatics and transcriptional mapping were used to identify high-content multiple features that provide biomarkers for the development of a rational drug screening platform for discovering novel chemotherapeutics that target cell division. (c) 2008 Published by Elsevier Ltd.
引用
收藏
页码:420 / 429
页数:10
相关论文
共 50 条
  • [31] Hybridization Approach to Drug Discovery Inhibiting Mycobacterium tuberculosis-An Overview
    Zampieri, Daniele
    Mamolo, Maria G.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2021, 21 (09) : 777 - 788
  • [32] In vitro drug discovery models for Mycobacterium tuberculosis relevant for host infection
    Parish, Tanya
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (03) : 349 - 358
  • [33] Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis
    Slayden, Richard A.
    Knudson, Dennis L.
    Belisle, John T.
    MICROBIOLOGY-SGM, 2006, 152 : 1789 - 1797
  • [34] Structures of Glycinamide Ribonucleotide Transformylase (PurN) from Mycobacterium tuberculosis Reveal a Novel Dimer with Relevance to Drug Discovery
    Zhang, Zhening
    Caradoc-Davies, Tom T.
    Dickson, James M.
    Baker, Edward N.
    Squire, Christopher J.
    JOURNAL OF MOLECULAR BIOLOGY, 2009, 389 (04) : 722 - 733
  • [35] Molecular genetics of Mycobacterium tuberculosis in relation to the discovery of novel drugs and vaccines
    Kana, BD
    Mizrahi, V
    TUBERCULOSIS, 2004, 84 (1-2) : 63 - 75
  • [36] How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery
    Bhagwat, Amala
    Deshpande, Aditi
    Parish, Tanya
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [37] Modeling synergistic drug inhibition of Mycobacterium tuberculosis growth in murine macrophages
    Fang, Xin
    Wallqvist, Anders
    Reifman, Jaques
    MOLECULAR BIOSYSTEMS, 2011, 7 (09) : 2622 - 2636
  • [38] Artificial intelligence in drug discovery: A new frontier in the fight against Mycobacterium tuberculosis
    Abavisani, Mohammad
    Khoshrou, Alireza
    Sahebkar, Amirhossein
    DRUG DISCOVERY TODAY, 2024, 29 (03)
  • [39] Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery
    Sean Ekins
    Joel S. Freundlich
    Judith V. Hobrath
    E. Lucile White
    Robert C. Reynolds
    Pharmaceutical Research, 2014, 31 : 414 - 435
  • [40] Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery
    Ekins, Sean
    Freundlich, Joel S.
    Hobrath, Judith V.
    White, E. Lucile
    Reynolds, Robert C.
    PHARMACEUTICAL RESEARCH, 2014, 31 (02) : 414 - 435